Pulmonary Hypertension Treatment
For patients with pulmonary arterial hypertension (PAH), treatment should begin with right heart catheterization for diagnosis confirmation, followed by vasoreactivity testing in idiopathic, heritable, or drug-induced PAH to identify the minority (~10%) who can be treated with high-dose calcium channel blockers; all other patients require targeted PAH therapies with initial dual oral combination therapy (endothelin receptor antagonist + phosphodiesterase-5 inhibitor) for low-to-intermediate risk patients, or triple therapy including a parenteral prostacyclin for high-risk patients. 1, 2
Diagnostic Evaluation
Right heart catheterization (RHC) is mandatory to confirm PAH diagnosis and must be performed at expert centers due to technical complexity and potential complications 1. The diagnostic criteria require:
- Mean pulmonary arterial pressure ≥25 mmHg (older guidelines) or ≥20 mmHg (newer definitions)
- Pulmonary vascular resistance >3 Wood Units
- Pulmonary artery wedge pressure ≤15 mmHg to exclude left heart disease 1
Critical pitfall: Many patients with left heart disease may have PAWP <15 mmHg after diuretic therapy, potentially leading to misdiagnosis. Consider volume challenge or exercise hemodynamics if left ventricular diastolic dysfunction is suspected 1.
Vasoreactivity Testing
Who Should Be Tested
Vasoreactivity testing is recommended ONLY for patients with idiopathic PAH (IPAH), heritable PAH (HPAH), or drug-induced PAH 1. Testing should be performed exclusively at expert centers using short-acting agents 3, 1.
Testing Protocol
The preferred agent is inhaled nitric oxide, with IV epoprostenol as an alternative 1. Adenosine may be considered but is no longer recommended in the most recent 2022 guidelines due to frequent side effects 4.
A positive response is strictly defined as:
- Reduction in mean PAP ≥10 mmHg AND
- Achieving absolute mean PAP ≤40 mmHg AND
- Increased or unchanged cardiac output 1
Critical warning: Never use oral or IV calcium channel blockers for acute vasoreactivity testing—this is explicitly contraindicated due to life-threatening complications 3, 1, 5.
Calcium Channel Blocker Therapy
Only the ~10% of IPAH patients meeting positive vasoreactivity criteria should receive CCB therapy 5. Use high doses:
- Nifedipine: 120-240 mg daily
- Diltiazem: 240-720 mg daily
- Amlodipine: up to 20 mg daily 5
Choose based on heart rate: Use nifedipine/amlodipine for bradycardia; diltiazem for tachycardia 5.
Mandatory reassessment: Perform repeat RHC at 3-4 months. If the patient is not in WHO functional class I-II with marked hemodynamic improvement, immediately add targeted PAH therapy 5. Only about half of acute responders remain long-term responders 5.
Targeted PAH Therapy for Non-Responders
Initial Treatment Strategy (2019-2022 Guidelines)
The treatment paradigm has shifted dramatically toward upfront combination therapy 6, 2:
For low-to-intermediate risk patients:
- Initial dual oral combination therapy with an endothelin receptor antagonist (ERA) + phosphodiesterase-5 inhibitor (PDE5i) 7, 2
For high-risk patients (WHO functional class IV):
- Initial triple therapy including IV epoprostenol + ERA + PDE5i 7, 2
- IV epoprostenol remains the treatment of choice for functional class IV patients 8
Available Drug Classes and Agents
The 2019 CHEST guideline provides the comprehensive list of approved medications 6:
Prostacyclin pathway:
- Epoprostenol (IV): 2 ng/kg/min, titrate as tolerated
- Treprostinil (IV/subcutaneous/inhaled/oral): multiple formulations
- Iloprost (inhaled): 2.5-5.0 mg, 6-9 inhalations daily
- Selexipag (oral prostacyclin receptor agonist): 200 mg BID, titrate to max 1600 mg BID
Endothelin receptor antagonists:
- Bosentan: 125 mg twice daily
- Ambrisentan: 5-10 mg once daily
- Macitentan: 10 mg once daily
Phosphodiesterase-5 inhibitors:
- Sildenafil: 20 mg every 8 hours
- Tadalafil: 40 mg once daily
Soluble guanylate cyclase stimulator:
- Riociguat: 0.5-1.0 mg every 8 hours, titrate to max 2.5 mg 6
Novel Therapy: Sotatercept
The 2026 ERS guidelines provide a strong recommendation for sotatercept (activin signaling inhibitor) in patients already receiving PAH drugs who remain at intermediate-low, intermediate-high, or high risk during follow-up 2. This represents the first disease-modifying biologic targeting the transforming growth factor beta superfamily, addressing underlying vascular remodeling rather than just vasodilation 2.
Important limitation: Evidence for sotatercept in low-risk patients is insufficient; decisions should be individualized 2.
Sequential Combination Therapy
For patients inadequately responding to initial monotherapy or dual therapy, add agents from different pathways 7. The 2019 CHEST update emphasizes that combination therapy should target multiple pathophysiologic pathways simultaneously 6.
Follow-Up and Risk Reassessment
Perform follow-up assessments every 3-6 months in stable patients using multidimensional risk stratification tools 7. The 2026 ERS guidelines suggest repeat RHC to guide treatment escalation in intermediate-to-high risk patients, though evidence for low-risk patients is limited 2.
Supportive and General Measures
Anticoagulation
- Warfarin is recommended for IPAH patients (Grade B recommendation) 3
- Consider anticoagulation for PAH associated with other conditions (scleroderma, congenital heart disease), though evidence is weaker 3
Oxygen Therapy
Maintain oxygen saturation >90% at all times using supplemental oxygen as needed 3. This is particularly important as hypoxemia is a potent pulmonary vasoconstrictor 3.
Diuretics
Use diuretics for right heart failure with peripheral edema or ascites. Maintain near-normal intravascular volume but avoid excessive diuresis causing hypotension 3.
Pregnancy
Pregnancy must be avoided or termination recommended in all PAH patients (Grade A recommendation) 3, 1, 7. This is a consistent strong recommendation across all guidelines.
Immunizations
Vaccinate against influenza and pneumococcal pneumonia; treat respiratory infections aggressively 3, 5.
Advanced Therapies
For refractory patients failing medical therapy:
Key Differences Between Guidelines
The 2004 ACCP guidelines 3 were more conservative, emphasizing monotherapy escalation. The 2015-2016 ESC/ERS guidelines 1, 7 introduced stronger recommendations for combination therapy. The 2019 CHEST update 6 solidified upfront combination as standard. The 2026 ERS guidelines 2 add sotatercept as a major advancement, representing the first non-vasodilator disease-modifying therapy.
The most recent high-quality evidence strongly supports aggressive upfront combination therapy rather than sequential monotherapy escalation, as this approach improves morbidity and mortality outcomes 2.